Alya Clause Samples
Alya. Alya, developed by the team of ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ at the Barcelona Supercomputing Centre, performs multi-scale, multi-physics biomechanical simulations. The specialties of Alya regarding biomedical sciences include cardiac electro-mechanic-flow simulations, from ion-channel kinetics up to organ level; and simulations of the respiratory system, particularly focusing on particle deposition. The simulations involve the solution of mathematical models at different scales using a FEM-based approach. Alya has been specifically optimised for the efficient use of supercomputing resources and does not employ external libraries. Within CompBioMed, our work is to collaborate with other partners (notably Oxford, UCL and SURF) setting up cardiovascular simulation scenarios on large-scale systems and supercomputers. BSC’s role is not only to research improving the accuracy and reach of our simulation platform, but also to make it more efficient in heterogeneous supercomputers, always with the exascale era in mind. Additionally, due to its versality, Alya is a paradigm of the three patterns: monlothic single physics applications, coupled multiphyscis (either ▇▇▇▇-▇▇▇▇ or Alya with other codes) and ensemble runs for, for instance, massive in-silico clinical trials. We consider that the only way of achieving these two objectives is by knowing deeply the architectures, porting the algorithms to them to get the best performance possible and optimizing all possible levels: core, chip, node and supercomputer (see D2.
Alya. Application description Technical specifications HPC usage and parallel performance
Alya. The purpose of Alya is to perform Cardiac Computational Mechanics simulations, from tissue to organ level. FEM-based fluid-electro-mechanical coupling solver, specifically designed for the efficient use of supercomputing resources. Non-clinical research ✔ Clinical research ✔ Clinical decision support ✔ Drug discovery Design & optimisation ✔ In silico clinical trials ✔ Personal health forecasting Contact email: ▇▇▇▇▇▇▇.▇▇▇▇▇▇▇@▇▇▇.▇▇ Estimated users at M0: 30 internal and 20 external Estimated users at M24: 35 internal and 30 external Estimated users at M36: 40 internal and 40 external (IMPORTANT NOTE: as Alya is used in different domains, the number of users is the grand total) URL: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/research-and-development/software-and-apps/software-list/alya User manual: ▇▇▇▇▇▇▇.▇▇▇▇▇▇▇@▇▇▇.▇▇ End user name ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇’▇ group ▇▇▇▇▇ ▇▇▇▇▇▇’▇ group JR Cebral’s group ELEM Biotech Dr. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇'s group Affiliation UOXF Universitat ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ University - University of Strathclyde Application area Cardiac modelling Cardiac modelling Vascular simulations (aneurisms) Cardiovascular modelling, respiratory system, cerebro-spinal fluid Cardiovascular modelling of the right side of the heart No. of associated users 6 5 2 3 1 Target use Research Research / educational Research Commercial, research Research Improvements implemented New models, efficiency, etc. N/A Efficiency Efficiency, models, deployment, etc. N/A Impact Papers Papers Papers Product design, media release, papers N/A yet Use of any e- infrastructure available via CompBioMed BSC and EPCC BSC BSC BSC BSC
Alya. Alya, developed by the team of ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ at the Barcelona Supercomputing Centre, performs multi-scale, multi-physics biomechanical simulations. The specialties of Alya regarding biomedical sciences include cardiac electro-mechanic-flow simulations, from ion-channel kinetics up to organ level; and simulations of the respiratory system, particularly focusing on particle deposition. The simulations involve the solution of mathematical models at different scales using a FEM-based approach. Alya has been specifically optimised for the efficient use of supercomputing resources and does not employ external libraries. Alya is available for use by research scientists on MareNostrum, ▇▇▇▇▇▇, and ▇▇▇▇▇▇▇▇▇; for clinical and industrial users, BSC recommends users access it as a service, due to the complexity involved with setting up simulations. To this purpose BSC has launched a spin- off (ELEM Biotech [5]) that will provide commercial software-as-a-service to medical device, pharmaceutical and biomedical industries using Alya.
Alya